Channel Therapeutics Corporation

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly To Discover, Develop Oligonucleo

OS Therapies Incorporated launched the 14th biopharmaceutical company initial public offering in the US in 2024 on 31 July, selling 1.6 million shares at $4 each to gross $6.4m in the smallest IPO so

Rapport Therapeutics Inc. charted a path for its initial public offering and executed the IPO according to the plan it laid out for investors, reaping a slight reward on its first day of trading on 7

The market for biopharmaceutical company initial public offerings and follow-on public offerings has become more friendly this year, but some firms still are circumventing the public offering route an